COVID-19 vaccine: AstraZeneca dose shows strong immune response in elderly; Pfizer likely to deliver by December

According to the latest report in Reuters, the potential Coronavirus vaccine produced by AstraZeneca Plc and Oxford University showed promising results during trials in elderly people. On the other hand, the deliveries of BioNTech-Pfizer vaccines could come by early December

Royal Enfield unveiled its SG650 concept motorcycle at EICMA 2021: check the specifications

Since the outbreak of COVID-19 pandemic, we all have been hopeful of the vaccine's findings. According to the latest report in Reuters, the potential Coronavirus vaccine produced by AstraZeneca Plc and Oxford University showed promising results during trials in elderly people. It may protect some of the most vulnerable affected individuals. Researchers stated that data from mid-stage trials showed that those aged over 70 could build strong immunity.

Maheshi Ramasamy, a consultant and a co-lead investigator at the Oxford Vaccine Group mentioned that the robust antibody and T-cell responses seen in older people in our study are encouraging. The populations at greatest risk include people with existing health conditions and older adults. This vaccine might help to protect some of the most exposed people in society. Later-stage research (Phase III trials) are also ongoing to confirm the finding, to test whether the vaccine protects against infection in a broad range of people, including people with underlying health conditions.

Recently, Ugur Sahin BioNTech, Chief Executive stated that deliveries of BioNTech-Pfizer vaccines could come by early December if everything goes well. 

While speaking to Reuters TV he said, "If all goes well I could imagine that we gain approval (from US FDA) in the second half of December and start deliveries before Christmas, but really only if all goes positively".

On Wednesday, the drugmaker Pfizer said that their coronavirus vaccine candidate has shown 95 per cent efficiency in the late-stage trial. They said the effectiveness of the vaccine developed with German partner BioNTech SE was constant across age and ethnicity demographics, and that there were no major side effects, a sign that the immunization could be employed broadly around the world.

Meanwhile, the third phase of Indian vaccine Covaxin trials is set to begin in Haryana on November 20. The vaccine is being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

This article is published on Goodnewwws with an aim to spread positive news from within our country and all around the world to uplift and inspire millions to become more optimistic.